260 related articles for article (PubMed ID: 21187973)
1. Markers of tumor-initiating cells predict chemoresistance in breast cancer.
Gong C; Yao H; Liu Q; Chen J; Shi J; Su F; Song E
PLoS One; 2010 Dec; 5(12):e15630. PubMed ID: 21187973
[TBL] [Abstract][Full Text] [Related]
2. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
3. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
[TBL] [Abstract][Full Text] [Related]
4. ABCG2 is a potential marker of tumor-initiating cells in breast cancer.
Sicchieri RD; da Silveira WA; Mandarano LR; de Oliveira TM; Carrara HH; Muglia VF; de Andrade JM; Tiezzi DG
Tumour Biol; 2015 Dec; 36(12):9233-43. PubMed ID: 26091795
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells.
Lin L; Hutzen B; Lee HF; Peng Z; Wang W; Zhao C; Lin HJ; Sun D; Li PK; Li C; Korkaya H; Wicha MS; Lin J
PLoS One; 2013; 8(12):e82821. PubMed ID: 24376586
[TBL] [Abstract][Full Text] [Related]
6. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
[TBL] [Abstract][Full Text] [Related]
7. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.
Azzam DJ; Zhao D; Sun J; Minn AJ; Ranganathan P; Drews-Elger K; Han X; Picon-Ruiz M; Gilbert CA; Wander SA; Capobianco AJ; El-Ashry D; Slingerland JM
EMBO Mol Med; 2013 Oct; 5(10):1502-22. PubMed ID: 23982961
[TBL] [Abstract][Full Text] [Related]
8. The role of ALDH1A1 in contributing to breast tumour aggressiveness: A study conducted in an African population.
Gyan E; Green A; Ahenkorah-Fondjo L; Jackson A; Toss MS; Akakpo PK; Derkyi-Kwarteng L; Rahman GA; Owiredu W
Ann Diagn Pathol; 2021 Apr; 51():151696. PubMed ID: 33460998
[TBL] [Abstract][Full Text] [Related]
9. CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549.
Roudi R; Madjd Z; Ebrahimi M; Samani FS; Samadikuchaksaraei A
Cell Mol Biol Lett; 2014 Mar; 19(1):23-36. PubMed ID: 24363164
[TBL] [Abstract][Full Text] [Related]
10. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
[TBL] [Abstract][Full Text] [Related]
11. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer.
Seo AN; Lee HJ; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
Br J Cancer; 2016 May; 114(10):1109-16. PubMed ID: 27115469
[TBL] [Abstract][Full Text] [Related]
12. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.
Lee HE; Kim JH; Kim YJ; Choi SY; Kim SW; Kang E; Chung IY; Kim IA; Kim EJ; Choi Y; Ryu HS; Park SY
Br J Cancer; 2011 May; 104(11):1730-8. PubMed ID: 21559013
[TBL] [Abstract][Full Text] [Related]
13. [Pilot study on the correlation between high incidence of CD44+/CD24 -/low/ABCG2- cells and poor prognosis in breast cancer].
Gong JF; Yuan YH; Song GH; Yu J; Han Y; Jia J; Ren J
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Oct; 40(5):465-70. PubMed ID: 18931706
[TBL] [Abstract][Full Text] [Related]
14. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
15. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H; Srour EF; Badve S
Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
[TBL] [Abstract][Full Text] [Related]
17. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
Sinha A; Paul BT; Sullivan LM; Sims H; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
Oncotarget; 2017 Feb; 8(6):10114-10135. PubMed ID: 28052035
[TBL] [Abstract][Full Text] [Related]
18. Association of CD44
Chekhun VF; Lukianova NY; Chekhun SV; Bezdieniezhnykh NO; Zadvorniy TV; Borikun TV; Polishchuk LZ; Klyusov OМ
Exp Oncol; 2017 Sep; 39(3):203-211. PubMed ID: 28967645
[TBL] [Abstract][Full Text] [Related]
19. Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression.
Vesuna F; Lisok A; Kimble B; Raman V
Neoplasia; 2009 Dec; 11(12):1318-28. PubMed ID: 20019840
[TBL] [Abstract][Full Text] [Related]
20. A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer.
Sambi M; Samuel V; Qorri B; Haq S; Burov SV; Markvicheva E; Harless W; Szewczuk MR
Drug Des Devel Ther; 2020; 14():1995-2019. PubMed ID: 32546966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
